<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>肺癌前沿 | wechat-feeds</title><link>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</link><description>传递最新肺癌信息</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 06 Apr 2021 23:22:55 +0800</pubDate><image><url>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</url><title>肺癌前沿 | wechat-feeds</title><link>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>TLCR | 流域分析法实时精准定位肺结节</title><link>https://mp.weixin.qq.com/s/eVMnHHvMK-AeHL9hN1k_xQ</link><description></description><content:encoded><![CDATA[TLCR | 流域分析法实时精准定位肺结节]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:15:38 +0800</pubDate></item><item><title>[Nat Rev Clin Oncol]PD-L1—免疫检查点抑制剂疗效反应的生物标志物</title><link>https://mp.weixin.qq.com/s/cYWshoaXKuvx8cYvZU_tTg</link><description></description><content:encoded><![CDATA[[Nat Rev Clin Oncol]PD-L1—免疫检查点抑制剂疗效反应的生物标志物]]></content:encoded><pubDate>Mon, 05 Apr 2021 21:27:34 +0800</pubDate></item><item><title>IOHK 2021免疫肿瘤学大会（香港）</title><link>https://mp.weixin.qq.com/s/1ZUuz3WTG8xfxybwBU3mMA</link><description></description><content:encoded><![CDATA[IOHK 2021免疫肿瘤学大会（香港）]]></content:encoded><pubDate>Fri, 02 Apr 2021 16:53:44 +0800</pubDate></item><item><title>JTO┃肺癌转移进化轨迹</title><link>https://mp.weixin.qq.com/s/iezw2UcVdHJ_-gscVIhP9w</link><description></description><content:encoded><![CDATA[JTO┃肺癌转移进化轨迹]]></content:encoded><pubDate>Sun, 14 Mar 2021 21:39:58 +0800</pubDate></item><item><title>scDbs,“看见”不可见的P53抑癌基因/RAS致癌基因突变靶点</title><link>https://mp.weixin.qq.com/s/HnStbS1wWFlg4JdS176W2w</link><description></description><content:encoded><![CDATA[scDbs,“看见”不可见的P53抑癌基因/RAS致癌基因突变靶点]]></content:encoded><pubDate>Sat, 13 Mar 2021 19:01:36 +0800</pubDate></item><item><title>[Nat Rev Dis]重磅综述带你深入了解小细胞肺癌</title><link>https://mp.weixin.qq.com/s/7ywD0UXplimjJhXpR3HdRQ</link><description></description><content:encoded><![CDATA[[Nat Rev Dis]重磅综述带你深入了解小细胞肺癌]]></content:encoded><pubDate>Mon, 22 Feb 2021 19:12:12 +0800</pubDate></item><item><title>[JTCVS-述评] 临床IA期肺腺癌侵袭性“占卜图”</title><link>https://mp.weixin.qq.com/s/8NlKRCikKKYEhTQ19pE-DA</link><description></description><content:encoded><![CDATA[[JTCVS-述评] 临床IA期肺腺癌侵袭性“占卜图”]]></content:encoded><pubDate>Tue, 16 Feb 2021 11:59:10 +0800</pubDate></item><item><title>“太平洋的风”PACIFIC模式是否适用于驱动基因阳性III期肺癌？</title><link>https://mp.weixin.qq.com/s/0r3PEKkNpqUbNUe0Z_8fuQ</link><description></description><content:encoded><![CDATA[“太平洋的风”PACIFIC模式是否适用于驱动基因阳性III期肺癌？]]></content:encoded><pubDate>Mon, 15 Feb 2021 13:28:28 +0800</pubDate></item><item><title>CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛</title><link>https://mp.weixin.qq.com/s/EXCKX9IWemox2tWNhDm2TA</link><description></description><content:encoded><![CDATA[CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛]]></content:encoded><pubDate>Sun, 14 Feb 2021 08:18:01 +0800</pubDate></item><item><title>[JCOG0804]：2cm以下磨砂玻璃成分为主肺结节楔形或肺段切除范围已足够</title><link>https://mp.weixin.qq.com/s/6cmy9IfAkPV1JpNc-ntisQ</link><description></description><content:encoded><![CDATA[[JCOG0804]：2cm以下磨砂玻璃成分为主肺结节楔形或肺段切除范围已足够]]></content:encoded><pubDate>Sat, 16 Jan 2021 17:58:50 +0800</pubDate></item></channel></rss>